Navigation Links
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
Date:2/21/2008

NEW YORK, Feb. 21 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) will hold a conference call on Monday, February 25, 2008 at 8:30 a.m. EST to discuss the fourth quarter and year-end 2007 financial results and business outlook for 2008. Michael S. Weiss, Chairman and Chief Executive Officer of the Company, will host the call. Keryx will announce its financial results for this period in a press release to be issued prior to the call.

In order to participate in the conference call, please call 1-877-874-1565 (U.S.), 1-719-325-4750 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

The press release announcing our financial results for this period will be posted on the Company's website, http://www.keryx.com, prior to the call.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide) oral gelcaps, previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase 3 and Phase 4 clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, iron- based compound that has the capacity to
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
10. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
11. Avicena Group to Present at Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015 US-Australian drug discovery company, ... confirmed it is committed to progressing its ground-breaking technology ... practicable and to ensure the Company delivers the best ... Iain Ross , said the Company currently had ... pre-clinical programs, discovery programs and academic partnerships and initiatives, ...
(Date:7/29/2015)...  HealthSouth Corporation (NYSE: HLS ), one ... services, offering both facility-based and home-based post-acute services, ... second quarter ended June 30, 2015. ... growth in both segments and an 11.0% increase ... and Chief Executive Officer of HealthSouth. "While reported ...
(Date:7/29/2015)... , July 29, 2015 ... announced the addition of the "Global Biosimilars ... offering. The Global Biosimilars Market, 2015 ... the rapidly growing biosimilars market. With the blockbuster ... to minimize costs, biosimilars are being viewed as ...
(Date:7/29/2015)... 2015  Therapath Neuropathology ( www.Therapath.com ), a ... VA and Military Medical centers both domestically and ... and Sweat Gland Nerve Fiber Density (SGNFD) for ... ). Demonstration of a reduction ... punch skin biopsy is a highly sensitive and ...
Breaking Biology Technology:Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27
... provide a,sensitive method to detect protease activity, measure ... of drug candidates. LI-COR,Biosciences now offers three different ... BACE, and IRDye 800CW/QC-1 CSP-3., "These substrates ... conjugated dye by our novel IRDye QC-1 quencher," ...
... Studies show that up to 30% of coffees ordered as ,decaf, ... ... Ever wonder whether the,coffee you had after dinner was really decaf? ... caffeine test strip from,Silver Lake Research, the leader in at-home water quality ...
... today that Gemstone Acquisition Corporation, a wholly-owned,subsidiary of ... purchase all,outstanding shares of common stock of Genelabs ... interest and less any required withholding,taxes. The tender ... announced,Agreement and Plan of Merger dated October 29, ...
Cached Biology Technology:LI-COR Introduces Three IRDye(R) Near-Infrared Fluorescence Resonance Energy Transfer (NIR-FRET) Protease Substrates 2Is Your Decaf Really Decaf? 2GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc. 2GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc. 3
(Date:7/30/2015)... July 30, 2015 Cellecta, Inc., a ... function analysis and biomarker discovery, announced the release ... Library targeting all human protein coding genes. CRISPR ... out" a gene,s function. Cellecta,s new Human Whole ... screening tool so that researchers can investigate in ...
(Date:7/23/2015)... , July 23, 2015 Research ... addition of the "Global Outlook of the ... offering. The global biometrics market ... public and commercial applications owing to the uptake ... witness a transformation that enhances the growth of ...
(Date:7/20/2015)... 2015  Acuity Market Intelligence,s latest research "The ... Commerce and Privacy" forecasts that between 2014 and ... be downloaded to smart mobile devices by 2.2 ... is projected to generate more than $67.9 billion ... forecast period.    "Biometrics is at ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
... A new study compares the relative rate of molecular evolution ... wanted to know whether evolution marches on at a steady pace ... of individual letters of the genetic code occur more rapidly ... study appears in the Proceedings of the Royal Society B ...
... Ga. - A well-documented suppressor of immunity that,s used ... to change its spots, researchers report. In the ... 2,3-dioxegenase, or IDO, also appears capable of helping key ... the invader, said Dr. Tracy L. McGaha, immunologist at ...
... 7, 2014   Dynasil Corporation of America ("Dynasil" ... developer of sensing, detection and analysis technology for homeland ... has regained compliance with the $1.00 minimum bid price ... As previously announced, on March 26, 2013, ...
Cached Biology News:Of lice and men (and chimps): Study tracks pace of molecular evolution 2Of lice and men (and chimps): Study tracks pace of molecular evolution 3Finding about classic suppressor of immunity points toward new therapies for bad infections 2Finding about classic suppressor of immunity points toward new therapies for bad infections 3Dynasil Regains Compliance with NASDAQ Listing Requirements 2
... leading provider of X-ray crystallography services ... screening services to its pharmaceutical and ... binding of drug-like fragments to the ... targets, allowing scientists to develop novel, ...
...
... acetylcholinesterase (AChE) activity. This is a highly ... non-radioactive and easy to use assay for ... acetylcholine. A series of coupled enzyme reactions ... a change in luminescence. Inhibitors of AChE ...
Rabbit polyclonal to Vitronectin ( Abpromise for all tested applications). Antigen: Full length native Vitronectin (Cow) Entrez Gene ID: 7448 Swiss Protein ID: P04004...
Biology Products: